PeriRx is the premier developer of a breakthrough, non-invasive, oral diagnostic technology that will help healthcare professionals and their patients improve their long-term health. The company has developed a painless saliva test that uses proven bio-chemistry analytics at high sensitivity and specificity to enable early disease risk detection. This early detection of treatable diseases can enhance patient wellness while reducing the cost of healthcare.
PeriRx is introducing SaliMark™ OSCC, its first commercial saliva test for the early detection of oral squamous cell carcinoma. According to the National Institutes of Health, oral cancer is the sixth most common cancer in the world. This disease is diagnosed in over 45,000 American patients per year, and of that, over 8000 of those patients die per year – a death every hour of every single day.
PeriRx is also developing early disease detection tests based upon licensed technology from UCLA to aid in the accurate and painless diagnosis of lung cancer, Sjögren’s Syndrome, diabetes type 1 and 2, and periodontal disease.
SaliMark™ OSCC: Oral Cancer Salivary Diagnostic Test
PeriRx’s first product is SaliMark™ OSCC – A risk stratification test recommended for use by the clinician when suspicious lesions are observed and additional testing is warranted. These discriminatory salivary biomarkers have been clinically-validated in multiple large trials including studies in collaboration with the National Cancer Institute and with premiere US academic medical centers such as the University of Michigan, Michigan State University and the Providence Health System in Detroit.